Survival changes in Patients with Synovial Sarcoma, 1983-2012

Abstract

Background: Synovial sarcoma (SyS) is a rare malignancy that typically invades the extremities and occurs predominantly in adolescents. Studies on incidence and survival in SyS that were based on a large population had not been reported yet.Methods: To evaluate changes in incidence and survival in SyS over three decades, we accessed data on SyS cases in each decade between 1983 and 2012 (1983-1992, 1993-2002, and 2003-2012) from the Surveillance, Epidemiology, and End Results (SEER) database. The survival difference between decades, age groups, sexes, race, pathologic types, sites, stages and socioeconomic status (SES) over three decades were accessed by comparing Kaplan-Meier curves.Results: We located 2,070 SyS cases in 18 SEER registry regions between 1983 and 2012. Our study demonstrated that the incidence of SyS per 1,000,000 continued to increase from 0.906 to 1.348 to 1.548 in the total population and in most age groups and that the age of incidence peak was 15-29 years in three decades. But, the survival of patients with SyS did not significantly improve throughout the three decades, with 5-year survival rates of 69.4%, 61.1% and 60.5% respectively (p > 0.05). Interestingly, the widening survival gaps among races, sexes, pathological types and various SES over time were observed, with narrowing p values.Conclusions: This study demonstrated the increasing incidence and unimproved survival rates across three decades in a large sample, indicating the urgency for further development of diagnosis, improving health care providers' awareness of SyS and lead to the development of novel treatments.

The Epidemiological Trend of Acute Myeloid Leukemia in Childhood: a Population-Based Analysis

“…In addition, racial and socioeconomic status (SES) inequalities continue to increase in the healthcare system, and more importantly, the eye-popping gaps have been confirmed to be associated with survival imbalance among cancer patients [15,16]. Hence, we analyzed the general trends of incidence and survival as well as the survival trends by race, age, and SES via a population-based database in the U.S.A.…”

Monophasic synovial sarcoma as a cause of obstructive ileus: Case report

“…Previous studies reported metastases in 50% of those cases, while the 5-year survival is 60.5% (6,12,13). Additionally, some studies have shown a 10-year survival rate ranging between 24 and 68% (6,(12)(13)(14). The most common metastases are found in the lungs, followed by lymph nodes, bone and liver.…”

“…It is of note that synovial sarcoma can occur in any region and at any age, but the peak incidence is the third decade and the most common site, the extremities (5). The incidence of synovial sarcomas was 0.9 in 1984, while in 2012 it was found to be 1.548/100,000 population (6). Older age, tumor size >5 cm, as well as trunk location have been characterized as risk factors for late stage disease.…”

“…For cases with localized, low-risk disease treatment involves surgical resection and, in some cases, (neo)adjuvant radiotherapy (12). Previous studies reported metastases in 50% of those cases, while the 5-year survival is 60.5% (6,12,13). Additionally, some studies have shown a 10-year survival rate ranging between 24 and 68% (6,(12)(13)(14).…”

PRAME and HLA Class I expression patterns make synovial sarcoma a suitable target for PRAME specific T-cell receptor gene therapy

“…Survival did not substantially improve over the last three decades. 2,3 Patients with localized disease have a 10-year survival rate of 69% that drops to below 10% in patients with metastatic disease, 4 illustrating the need for better treatment options for patients with advanced stages of SS. Multiple trials are running using inhibiting molecules to target metabolic pathways in SS and other trials target SS with monoclonal antibodies.…”